HIV Glasgow 2022 | MIMS Malaysia

Age, sex, syphilis risk factors for COVID-19 in PLHIV

Roshini Claire Anthony, 20221130180001

Among people living with HIV (PLHIV), young women and patients with active syphilis appeared to be at an elevated risk of contracting COVID-19, according to a cross-sectional study presented at HIV Glasgow 2022.

TB rates elevated after ART initiation in PLHIV

Roshini Claire Anthony, 20221121150001

People living with HIV (PLHIV) who initiate antiretroviral therapy (ART) are at an increased risk of developing tuberculosis (TB), particularly in the first 3 months after starting ART, according to a study presented at HIV Glasgow 2022.

Low use of CVD prevention strategies in people with HIV

Roshini Claire Anthony, 20221118180001

There is an underutilization of cardiovascular disease (CVD) prevention strategies in people living with HIV (PLHIV) who are at risk of CVD, according to a study presented at HIV Glasgow 2022.

Doravirine-lamivudine-tenofovir disoproxil well-tolerated as HIV postexposure prophylaxis

Tristan Manalac, 20221111090000

Among people with potential nonoccupational exposure to HIV, a single-tablet once-daily regimen (STR) of doravirine-lamivudine-tenofovir disoproxil is a well-tolerated postexposure prophylaxis (PEP) option, reports a study presented at the recently concluded 2022 HIV Glasgow Conference.

B/F/TAF keeps HIV RNA levels suppressed at 24 months

Tristan Manalac, 20221110090000

Implementing the bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) treatment regimen in routine clinical care can effectively suppress HIV in people living with HIV over 24 months of follow-up, reports a study presented at HIV Glasgow 2022.

Cabotegravir-rilpivirine regimen feasible in hospitals

Tristan Manalac, 20221109090000

A once-every-two-months (Q2M) dosing regimen of cabotegravir with rilpivirine long-acting (CAB+RPV LA) can be easily implemented in hospitals and draws high levels of acceptability, appropriateness, and feasibility feedback from healthcare staff, according to a study presented at the recently concluded 2022 HIV Glasgow Conference.

Two-drug dolutegravir-based regimen a valid alternative for pregnant women with HIV

Jairia Dela Cruz, 20221107140000

For pregnant women with HIV who are receiving dolutegravir (DTG)-based therapies, the two-drug regimen works just as well as three-drug regimens at keeping the viral load to "undetectable" levels without exerting serious adverse effects on neonatal outcomes, according to a study presented at HIV Glasgow 2022 Congress.

Switch to B/F/TAF sustains virologic suppression in adult PLHIV

Stephen Padilla, 20221107120000

Adult people with HIV-1 (PLHIV) who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) after initially taking dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) or DTG+F/TAF show a consistently high virologic suppression and have few discontinuations over 5 years of follow-up, according to a study presented at the HIV Glasgow 2022 Congress.

Once-a-day pill as switch option receives thumbs up across multiple HIV populations

Jairia Dela Cruz, 20221104140000

Switching to the once-a-day, fixed-dose pill that contains bictegravir, emtricitabine, and tenofovir (BIC/FTC/TAF) appears to be safe and effective in older HIV patients and in people living with HIV (PLHIV) with pretreatment or treatment-acquired resistance, in addition to yielding metabolic benefits, according to studies presented at HIV Glasgow 2022.

Detectable viral loads persist in one-third of PLHIV in Asia-Pacific region

Stephen Padilla, 20221104120000

Between 2015 and 2020, nearly a third of people living with HIV (PLHIV) in Asia-Pacific countries still show a detectable viral load, according to a study presented at the HIV Glasgow 2022 Congress.